Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis Publisher



Mirmosayyeb O1, 2, 3 ; Brand S4, 5, 6, 7, 8 ; Barzegar M1, 3 ; Afsharisafavi A9 ; Nehzat N1, 2, 10 ; Shaygannejad V1, 3 ; Bahmani DS4, 6, 11
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran
  2. 2. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, 14197-33151, Iran
  3. 3. Department of Neurology, Isfahan University of Medical Sciences, Isfahan, 81746-73461, Iran
  4. 4. Center of Depression, Stress and Sleep Disorders, Psychiatric Clinics (UPK), University of Basel, Basel, 4002, Switzerland
  5. 5. Division of Sport Science and Psychosocial Health, Department of Sport, Exercise, and Health, University of Basel, Basel, 4032, Switzerland
  6. 6. Substance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences (KUMS), Kermanshah, 6719851351, Iran
  7. 7. Sleep Disorders Research Center, Health Institute, Kermanshah University of Medical Sciences (KUMS), Kermanshah, 6719851351, Iran
  8. 8. School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, 1416753955, Iran
  9. 9. Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, 74877-94149, Iran
  10. 10. Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, 6135715794, Iran
  11. 11. Departments of Physical Therapy, University of Alabama at Birmingham, Birmingham, 35209, AL, United States

Source: Journal of Clinical Medicine Published:2020


Abstract

Background: Compared to the adult onset of multiple sclerosis (AOMS), both early-onset (EOMS) and late-onset (LOMS) are much less frequent, but are often under-or misdiagnosed. The aims of the present study were: 1. To compare demographic and clinical features of individuals with EOMS, AOMS and LOMS, and 2. To identify predictors for disability progression from relapsing remitting MS (RRMS) to secondary progressive MS (SPMS). Method: Data were taken from the Isfahan Hakim MS database. Cases were classified as EOMS (MS onset ≤18 years), LOMS (MS onset >50 years) and AOMS (MS >18 and ≤ 50 years). Patients’ demographic and clinical (initial symptoms; course of disease; disease patterns from MRI; disease progress) information were gathered and assessed. Kaplan–Meier and Cox proportional hazard regressions were conducted to determine differences between the three groups in the time lapse in conversion from relapsing remitting MS to secondary progressive MS. Results: A total of 2627 MS cases were assessed; of these 127 were EOMS, 84 LOMS and 2416 AOMS. The mean age of those with EOMS was 14.5 years; key symptoms were visual impairments, brain stem dysfunction, sensory disturbances and motor dysfunctions. On average, 24.6 years after disease onset, 14.2% with relapsing remitting MS (RRMS) were diagnosed with secondary progressive MS (SPMS). The key predictor variable was a higher Expanded Disability Status Scale (EDSS) score at disease onset. Compared to individuals with AOMS and LOMS, those with EOMS more often had one or two relapses in the first two years, and more often gadolinium-enhancing brain lesions. For individuals with AOMS, mean age was 29.4 years; key symptoms were sensory disturbances, motor dysfunctions and visual impairments. On average, 20.5 years after disease onset, 15.6% with RRMS progressed to SPMS. The key predictors at disease onset were: a higher EDSS score, younger age, a shorter inter-attack interval and spinal lesions. Compared to individuals with EOMS and LOMS, individuals with AOMS more often had either no or three and more relapses in the first two years. For individuals with LOMS, mean age was 53.8 years; key symptoms were motor dysfunctions, sensory disturbances and visual impairments. On average, 14 years after disease onset, 25.3% with RRMS switched to an SPMS. The key predictors at disease onset were: occurrence of spinal lesions and spinal gadolinium-enhancement. Compared to individuals with EOMS and AOMS, individuals with LOMS more often had no relapses in the first two years, and higher EDSS scores at disease onset and at follow-up. Conclusion: Among a large sample of MS sufferers, cases with early onset and late onset are observable. Individuals with early, adult and late onset MS each display distinct features which should be taken in consideration in their treatment. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Other Related Docs
24. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
27. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
39. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
48. Diagnosis and Management of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2016)